Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Fabry disease is a rare inherited condition that can cause fatty substances to build up in the body. Over time, this build-up can make the walls of the heart thicker, which may lead to heart problems. This clinical trial looks at whether an experimental medicine called venglustat works well to reduce heart muscle thickening in people with Fabry disease. Adults aged 18 to 65 will be put into one of two groups by chance. One group will take venglustat tablets, while the other group will receive usual standard care treatments. The main part of the study lasts about 18 months, with hospital visits every three to six months for scans and health checks. If the trial goes well, participants may have the option to stay on venglustat for up to five years.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Sanofi
Einschreibeziel
104
Starten
03 May 2022
Geschätzte Fertigstellung
06 Dec 2027

Worum geht es in dieser Studie?

Fabry disease is a rare genetic condition where the body lacks an enzyme needed to clear out certain fatty substances. As these fats slowly build up inside cells, they can damage vital organs over time. One common and serious complication is an enlarged or thickened heart wall, known as left ventricular hypertrophy. When the heart muscle becomes too thick, it has to work much harder to pump blood around the body.

Currently, people with Fabry disease usually receive enzyme replacement therapy through regular intravenous drips, or take specific oral tablets if their genetic type allows. This study is testing a newer tablet medicine called venglustat. Instead of replacing the missing enzyme, venglustat aims to stop the fatty substances from being made in the first place, which may help shrink or stabilise the thickened heart muscle.

Researchers want to see if venglustat works better or just as well as existing standard treatments. Finding new ways to protect the heart could give people living with Fabry disease more treatment choices and potentially improve their long-term health and quality of life.

Wichtige Erkenntnisse

  • Tests whether a new tablet, venglustat, helps reduce heart thickening in Fabry disease.
  • Open to adults aged 18 to 65 with a confirmed diagnosis of Fabry disease.
  • Compares the new tablet against standard NHS therapies over 18 months.
  • Clinic visits and heart scans occur every 3 to 6 months.
  • An optional long-term extension may allow participants to continue treatment for up to 5 years.

Wer könnte berechtigt sein?

This trial is for men and women aged between 18 and 65 who have been diagnosed with Fabry disease and have noticeable thickening of their heart muscle. Participants can be people who are already on standard Fabry treatments or people who are not currently receiving treatment. Women must not be pregnant or breastfeeding, and all participants must agree to use effective contraception during the study.

You may not be able to take part if you have experienced serious heart problems in the past, such as a heart attack, stroke, heart failure, or heart surgery. People with significant scarring in the heart, severe kidney disease, active liver problems, or serious untreated mental health conditions will also be excluded to ensure their safety.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am between 18 and 65 years old.
  2. I have a confirmed diagnosis of Fabry disease.
  3. My doctor has told me that my heart muscle is thickened (left ventricular hypertrophy).
  4. I have not had a stroke, heart attack, or major heart surgery.
  5. I do not have severe kidney or liver disease.
  6. I am not pregnant or breastfeeding, and I am willing to use reliable contraception.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join the trial, you will be placed into one of two groups by chance (randomised). You will either take venglustat tablets daily or receive one of the standard approved treatments for Fabry disease. The main treatment phase lasts around 18 months. During this time, you will visit the clinic every 3 to 6 months for regular health checks, blood tests, and heart MRI scans to measure your heart muscle. After finishing the initial 18 months, you may be invited to join an extension period where all participants receive venglustat, which can extend total participation up to roughly 5.3 years. You are free to stop participating at any time.

Potenzielle Risiken und Vorteile

Taking part may help reduce heart muscle thickening and offers regular, close monitoring by heart and rare disease specialists. However, there is no guarantee venglustat will improve your condition, and like all medicines, it may cause unforeseen side effects. You might also be placed in the standard care group rather than receiving the new drug. Participating requires regular hospital visits, scans, and blood tests. Taking part is completely voluntary, and you can leave the trial at any point without it affecting your standard NHS care.

Locations (54)

  • University of Alabama -The Kirklin Clinic- Site Number : 8400010
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten
  • University of California Los Angeles Medical Center- Site Number : 8400008
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Emory University School of Medicine - Atlanta- Site Number : 8400009
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten
  • Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten
  • Maryam Banikazemi, MD- Site Number : 8400001
    Verifizierte Postleitzahl
    Hawthorne, United States
  • Renal Disease Research Institute- Site Number : 8400012
    Verifizierte Postleitzahl
    Dallas, Vereinigte Staaten
  • University of Utah Health Hospital- Site Number : 8400006
    Verifizierte Postleitzahl
    Salt Lake City, Vereinigte Staaten
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
    Verifizierte Postleitzahl
    Fairfax, Vereinigte Staaten
  • Investigational Site Number : 0400001
    Verifizierte Postleitzahl
    Graz, Österreich
  • Investigational Site Number : 1240003
    Verifizierte Postleitzahl
    Calgary, Kanada
  • Investigational Site Number : 1240006
    Verifizierte Postleitzahl
    Edmonton, Kanada
  • Investigational Site Number : 1240002
    Verifizierte Postleitzahl
    Vancouver, Kanada

Häufige Fragen

What is Fabry disease?

Fabry disease is a rare genetic condition where a missing enzyme causes fatty substances to build up inside blood vessels and organs, including the heart and kidneys.

How is venglustat taken?

Venglustat is an oral medicine taken by mouth as a tablet.

Can I choose which treatment I receive?

No. A computer randomly decides whether you receive venglustat or a standard treatment to ensure the test results are fair and unbiased.

Will I have to pay for the study treatment?

No. Clinical trial medicines and all study-related tests are provided free of charge, and travel expenses are usually covered.

What happens if I decide to leave the trial early?

You are free to leave at any time. Your medical team will safely transition you back to your regular NHS treatment plan.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.